B. Riley Estimates Immunic’s FY2025 Earnings (NASDAQ:IMUX)

Immunic, Inc. (NASDAQ:IMUX) – B. Riley raised their FY2025 earnings per share estimates for shares of Immunic in a research note issued to investors on Tuesday, November 25th. B. Riley analyst W. Wood now expects that the company will post earnings of ($0.55) per share for the year, up from their previous forecast of ($0.78). The consensus estimate for Immunic’s current full-year earnings is ($0.94) per share. B. Riley also issued estimates for Immunic’s Q4 2025 earnings at ($0.08) EPS and FY2026 earnings at ($0.37) EPS.

Immunic (NASDAQ:IMUX) last released its earnings results on Thursday, November 13th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.05.

IMUX has been the topic of a number of other reports. Chardan Capital raised shares of Immunic to a “strong-buy” rating in a report on Wednesday, November 19th. HC Wainwright lowered their price target on Immunic from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Friday, November 14th. Weiss Ratings restated a “sell (e+)” rating on shares of Immunic in a research note on Tuesday. Roth Capital started coverage on Immunic in a research report on Friday, November 7th. They issued a “buy” rating and a $3.00 price objective for the company. Finally, LADENBURG THALM/SH SH raised Immunic to a “strong-buy” rating in a report on Thursday, October 16th. Two research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $7.40.

Immunic Price Performance

Shares of IMUX stock opened at $0.71 on Thursday. The company has a fifty day moving average price of $0.81 and a two-hundred day moving average price of $0.84. Immunic has a one year low of $0.56 and a one year high of $1.42. The stock has a market cap of $85.64 million, a P/E ratio of -0.76 and a beta of 1.53.

Hedge Funds Weigh In On Immunic

A number of large investors have recently made changes to their positions in the company. Qube Research & Technologies Ltd acquired a new stake in Immunic during the 3rd quarter worth approximately $29,000. Focus Partners Wealth lifted its holdings in shares of Immunic by 1.5% during the third quarter. Focus Partners Wealth now owns 2,581,587 shares of the company’s stock worth $2,276,000 after buying an additional 39,063 shares in the last quarter. Two Sigma Investments LP bought a new stake in shares of Immunic in the third quarter valued at about $52,000. HB Wealth Management LLC bought a new stake in shares of Immunic in the third quarter valued at about $81,000. Finally, Virtu Financial LLC acquired a new position in shares of Immunic in the third quarter valued at about $99,000. Institutional investors own 51.82% of the company’s stock.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.